Results 21 to 30 of about 1,300 (156)
Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]
Exploration of CardiologyBackground: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman +9 more
doaj +1 more source
Drugs, 2022 Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New ...
openaire +2 more sources
Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply [PDF]
The Lancet, 2021 reply to ...
Jacoby D. +4 more
openaire +2 more sources
Low-Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real-World Study in China. [PDF]
Cardiovasc TherAims To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results This single‐center observational study (Zhongshan Hospital, China; Oct 2024–Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55 ...
Yang W +8 more
europepmc +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Long‐term efficacy and safety of mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy are unknown. Methods Patients who completed the 30‐week, double‐blind, placebo‐controlled treatment period in EXPLORER‐CN (A Study to ...
Zhuang Tian +15 more
doaj +1 more source
Future Science OA, 2023 Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies ...
Areeba Memon +9 more
doaj +1 more source
Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights
The Journal of Physiology, EarlyView.Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March
Silvia Marchianò +18 more
wiley +1 more source
Clinical and Translational ScienceObstructive hypertrophic cardiomyopathy (oHCM) is a subtype of HCM characterized by left ventricular outflow tract obstruction resulting from cardiac muscle hypertrophy and anatomic alterations in the mitral valve and apparatus.
Xiaojie Wu +18 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT In older patients receiving mavacamten, a reduction in NT‐proBNP levels may coexist with persistent severe LVOTO. Nurses should interpret this biomarker–echocardiography discordance as a safety signal and maintain structured cardiovascular surveillance rather than assuming treatment success based solely on biomarker improvement.
Feifei Wang
wiley +1 more source
Cardiology and TherapyIntroduction Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with symptomatic obstructive hypertrophic ...
Zhuang Tian +16 more
doaj +1 more source